発表・論文

【Original article】

Tsujimoto T, Kajio H. Four-Year Screening Interval and Vision-Threatening Retinopathy in Type 2 Diabetes Patients With Good Glycemic Control.
Mayo Clin Proc. 2021 Feb;96(2):322-331.

Tsujimoto T, Kajio H. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
J Am Heart Assoc. 2020 Dec;9(23):e018827.

Tsujimoto T, Kajio H. Thiazide Use and Decreased Risk of Heart Failure in Nondiabetic Patients Receiving Intensive Blood Pressure Treatment.
Hypertension. 2020 Aug;76(2):432-441.

Tsujimoto T, Kajio H. Thiazide Use and Cardiovascular Events in Type 2 Diabetic Patients With Well-Controlled Blood Pressure.
Hypertension. 2019 Dec;74(6):1541-1550.

Tsujimoto T, Kajio H. Use of Nitrates and Risk of Cardiovascular Events in Patients with Heart Failure with Preserved Ejection Fraction.
Mayo Clin Proc. 2019 July;94(7):1210-1220.

Tsujimoto T, Kajio H. No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes taking non-steroidal anti-inflammatory drugs.
Diabetes Obes Metab. 2019 Aug;21(8):1978-1984.

Tsujimoto T, Kajio H. Optimal cardiac strategy based on the history of myocardial infarction in type 2 diabetic patients with coronary artery disease.
Sci Rep. 2019 Mar 5;9(1):3502.

Tsujimoto T, Kajio H. Strategies for glycemic control in nonobese and obese type 2 diabetic patients with coronary artery disease.
Int J Cardiol. 2019 May 1;282:1-6.

Tsujimoto T, Kajio H. Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease.
J Am Heart Assoc. 2019 Jan 22;8(2):e011207.

Tsujimoto T, Kajio H. Intensive Blood Pressure Treatment for Resistant Hypertension.
Hypertension. 2019 Feb;73(2):415-423.

Tsujimoto T, Kajio H. Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease.
Int J Cardiol. 2018 Dec 15;273:1-7.

Tsujimoto T, Kajio H. Benefits of Intensive Blood Pressure Treatment in Patients With Type 2 Diabetes Mellitus Receiving Standard but Not Intensive Glycemic Control.
Hypertension. 2018 Aug;72(2):323-330.

Tsujimoto T, Kajio H. Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction.
Sci Rep. 2018 Jun 22;8(1):9556.

Tsujimoto T, Kajio H. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.
Eur J Prev Cardiol. 2018 Aug;25(12):1268-1277.

Tsujimoto T, Kajio H. Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction.
Int J Cardiol. 2018 Jul 15;263:69-74.

Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T. Risk of All-Cause Mortality in Diabetic Patients Taking β-Blockers.
Mayo Clin Proc. 2018 Apr;93(4):409-418.

Tsujimoto T, Kajio H. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease.
Int J Cardiol. 2018 Mar 15;255:111-117

Tsujimoto T, Kajio H. Abdominal Obesity Is Associated with an Increased Risk of All-cause Mortality in Patients with Heart Failure with Preserved Ejection Fraction.
J Am Coll Cardiol 2017 Dec 5;70(22):2739-2749

Tsujimoto T, Kajio H, Sugiyama T. Statin Therapy in Patients with Low Serum Levels of Low-density Lipoprotein Cholesterol.
Am J Cardiol. 2017 Dec 1;120(11):1947-1954.

Tsujimoto T, Kajio H, Sugiyama T. Favourable Changes in Mortality in People with Diabetes - U.S. NHANES 1999-2010.
Diabetes Obes Metab. 2018 Jun;20(1):85-93.

Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers.
Hypertension. 2017 Jul;70(1):103-110.

Tsujimoto T, Kajio H, Sugiyama T. Association between caffeine intake and all-cause and cause-specific mortality: A population-based prospective cohort study.
Mayo Clin Proc. 2017;92:1190-1202.

Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population-based observational study.
Int J Cancer. 2017 Jul 1;141(1):102-111.

Tsujimoto T, Sugiyama T, Kajio H. Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.
Diabetes Obes Metab. 2017 Jun;19(6):800-808.

Tsujimoto T. Reply to the letter: "Sweet taste disorder and vascular complications in patients with abnormal glucose tolerance".
Int J Cardiol. 2017 Feb 15;229:37.

Tsujimoto T, Kajio H, Sugiyama T. Risks for Cardiovascular and Cardiac Deaths in Nonobese Patients With Diabetes and Coronary Heart Disease.
Mayo Clin Proc. 2016 Nov;91(11):1545-1554.

Tsujimoto T, Kajio H, Sugiyama T. Obesity, diabetes, and length of time in the United States: Analysis of National Health and Nutrition Examination Survey 1999 to 2012.
Medicine (Baltimore). 2016 Aug;95(35):e4578.

Tsujimoto T, Sugiyama T, Yamamoto-Honda R, Kishimoto M, Noto H, Morooka M, Kubota K, Kamimura M, Hara H, Kajio H, Kakei M, Noda M. Beneficial effects through aggressive coronary screening for type 2 diabetes patients with advanced vascular complications.
Medicine (Baltimore). 2016 Aug;95(33):e4307.

Tsujimoto T, Sugiyama T, Noda M, Kajio H. Intensive Glycemic Therapy in Patients With Type 2 Diabetes on β-Blockers.
Diabetes Care. 2016 Oct;39(10):1818-26.

Tsujimoto T, Imai K, Kanda S, Kakei M, Kajio H, Sugiyama T. Sweet taste disorder and vascular complications in patients with abnormal glucose tolerance.
Int J Cardiol. 2016 Oct 15;221:637-41.

Tsujimoto T, Yamamoto-Honda R, Kajio H, Kishimoto M, Noto H, Hachiya R, Kimura, A, Kakei M, Noda M. Accelerated decline of renal function in type 2 diabetes following severe hypoglycemia.
J Diabetes Complications. 2016 May-Jun;30(4):681-5.

Tsujimoto T, Yamamoto-Honda R, Kajio H, Kishimoto M, Noto H, Hachiya R, Kimura, A, Kakei M, Noda M. Effectiveness of Prior Use of Beta-Blockers for Preventing Adverse Influences of Severe Hypoglycemia in Patients With Diabetes: An Observational Study.
Medicine (Baltimore). 2015 Sep;94(39):e1629.

Tsujimoto T, Yamamoto-Honda R, Kajio H, Kishimoto M, Noto H, Hachiya R, Kimura A, Kakei M, Noda M. High risk of abnormal QT prolongation in the early morning in diabetic and non-diabetic patients with severe hypoglycemia.
Ann Med. 2015 May;47(3):238-44.

Tsujimoto T, Yamamoto-Honda R, Kajio H, Kishimoto M, Noto H, Hachiya R, Kimura A, Kakei M, Noda M. Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients.
Diabetes Care. 2014;37:217-25.

Tsujimoto T, Yamamoto-Honda R, Kajio H, Kishimoto M, Noto H, Hachiya R, Kimura A, Kakei M, Noda M. Prediction of 90-day mortality in patients without diabetes by severe hypoglycemia: blood glucose level as a novel marker of severity of underlying disease.
Acta Diabetol. 2015;52:307-14.

Tsujimoto T, Yamamoto-Honda R, Kajio H, Kishimoto M, Noto H, Hachiya R, Kimura A, Kakei M, Noda M. Seasonal Variations of Severe Hypoglycemia in Patients with Type 1 Diabetes, Type 2 Diabetes, and Non-Diabetes: Clinical Analysis of 578 Hypoglycemia Cases.
Medicine (Baltimore). 2014. Nov;93(23):e148.

Tsujimoto T, Yamamoto-Honda R. Clinical Conditions during Severe Hypoglycemia in Patients with Diabetes.
Diabetol Int. 2014;5:81–83.

Tsujimoto T, Kajio H, Takahashi Y, Kishimoto M, Noto H, Yamamoto-Honda R, Kamimura M, Morooka M, Kubota K, Shimbo T, Hiroe M, Noda M. Asymptomatic coronary heart disease in patients with type 2 diabetes with vascular complications: a cross-sectional study.
BMJ Open. 2011 Jan 1;1(2):e000139.

Tsujimoto T, Takaichi M, Endo H, Yasuda K, Kishimoto M, Noto H, Gomibuchi H, Yasuda H, Yamamoto-Honda R, Takahashi Y, Kajio H, Sasano H, Noda M. A patient with diabetes and breast cancer in whom virilization was caused by a testosterone-producing mature cystic teratoma containing a Brenner tumor.
Am J Med Sci. 2011 Jan;341(1):74-7.